Sprycel (Dasatinib) Patent Expiration, LOE Window & CMS Spending

Sprycel (Dasatinib) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2026-09-28, 10 AB generics, $780.5M 2024 CMS Part D & Medicaid spend, and 12 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN021986 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE Date2026-09-28
Last Listed Patent or Exclusivity Date2026-09-28
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors10
2024 CMS Total Public Spend$780.5M
2024 Medicare Part D Spend$518.3M
2024 Medicaid Spend$262.2M
Reported Wholesale Price Change (CA SB 17)12 WAC filings (max 20.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.